RegulatoryMay 15, 2026, 05:32 PM
Alaunos Therapeutics Faces Nasdaq Delisting Risk, Going Concern Doubt
AI Summary
Alaunos Therapeutics reported a net loss of $1.0 million for Q1 2026, with cash and cash equivalents of $0.35 million as of March 31, 2026, expected to fund operations only into Q2 2026. The company faces substantial doubt about its ability to continue as a going concern and received a Nasdaq notice for non-compliance with the minimum stockholders' equity requirement, risking delisting. The company is focused on its early preclinical Obesity and Metabolic Disorders Program.
Key Highlights
- Received Nasdaq notice on April 9, 2026, for non-compliance with $2.5M minimum stockholders' equity rule.
- Cash and cash equivalents were $0.35 million as of March 31, 2026.
- Cash resources are expected to fund operations only into the second quarter of 2026.
- Accumulated deficit reached $925.6 million as of March 31, 2026.
- Net loss for Q1 2026 was $1.0 million, compared to $1.073 million in Q1 2025.
- Total stockholders' equity was $1.288 million as of March 31, 2026.
- Identified a material weakness in the internal control environment.
- Board may pursue dissolution if the Obesity and Metabolic Disorders Program fails.
Price Impact
More from TCRT